Biostar Pharmaceuticals Stock Equity Positions Weight
BSPMDelisted Stock | USD 0.01 0.00 0.00% |
Biostar Pharmaceuticals fundamentals help investors to digest information that contributes to Biostar Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Biostar Pink Sheet. The fundamental analysis module provides a way to measure Biostar Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostar Pharmaceuticals pink sheet.
Biostar |
Biostar Pharmaceuticals Company Equity Positions Weight Analysis
Biostar Pharmaceuticals' Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
More About Equity Positions Weight | All Equity Analysis
Stock Percentage | = | % of Equities | in the fund |
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
CompetitionAccording to the company disclosure, Biostar Pharmaceuticals has an Equity Positions Weight of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Pharmaceuticals, Biotechnology & Life Sciences (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
All Next | Launch Module |
Biostar Fundamentals
Return On Equity | 0.0266 | ||||
Return On Asset | 0.0425 | ||||
Profit Margin | 2.94 % | ||||
Operating Margin | 8.76 % | ||||
Current Valuation | 316.46 K | ||||
Shares Outstanding | 2.64 M | ||||
Number Of Shares Shorted | 170.44 K | ||||
Price To Book | 0.01 X | ||||
Price To Sales | 0.0001 X | ||||
Revenue | 317.79 K | ||||
Gross Profit | 915.17 K | ||||
EBITDA | (1.7 M) | ||||
Net Income | (5.7 M) | ||||
Cash And Equivalents | 364.97 K | ||||
Cash Per Share | 0.14 X | ||||
Debt To Equity | 0.07 % | ||||
Current Ratio | 0.19 X | ||||
Book Value Per Share | 13.71 X | ||||
Cash Flow From Operations | 4.91 M | ||||
Short Ratio | 3.00 X | ||||
Earnings Per Share | 0.06 X | ||||
Target Price | 7.0 | ||||
Number Of Employees | 200 | ||||
Beta | -2923.36 | ||||
Market Capitalization | 94 | ||||
Total Asset | 42.5 M | ||||
Retained Earnings | 3.16 M | ||||
Working Capital | 9.07 M | ||||
Current Asset | 16.17 M | ||||
Current Liabilities | 7.1 M | ||||
Net Asset | 42.5 M |
About Biostar Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostar Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostar Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostar Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Biostar Pink Sheet
If you are still planning to invest in Biostar Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostar Pharmaceuticals' history and understand the potential risks before investing.
Transaction History View history of all your transactions and understand their impact on performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |